{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:15:26Z","timestamp":1794244526179,"version":"4.9.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372519"],"award-info":[{"award-number":["81372519"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin City","doi-asserted-by":"publisher","award":["22JCZDJC00450"],"award-info":[{"award-number":["22JCZDJC00450"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010590","name":"Tianjin Municipal Health Bureau","doi-asserted-by":"publisher","award":["TJWJ2021MS006"],"award-info":[{"award-number":["TJWJ2021MS006"]}],"id":[{"id":"10.13039\/501100010590","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Osimertinib resistance remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in tumor microenvironment (TME), however, its role in osimertinib resistance in NSCLC is not fully understood. In this study, it was found that CAFs promoted osimertinib resistance in NSCLC cells via elevating RNA m\n                    <jats:sup>7<\/jats:sup>\n                    G modification. Methyltransferase 1 (METTL1) in NSCLC cells mediated CAFs\u2019 effect on m\n                    <jats:sup>7<\/jats:sup>\n                    G modification, and METTL1 was associated with NSCLC progression and poor prognosis. Further study demonstrates that CAFs upregulated METTL1 in NSCLC cells by secreting HMGB1. By applying MeRIP-seq and RNA-seq, neuroepithelial cell transforming gene 1 (NET1) was identified as a target of METTL1, and enhanced m\n                    <jats:sup>7<\/jats:sup>\n                    G modification of NET1 increased NET1 expression and activated downstream AKT\/NF-\u03baB pathway. Importantly, reducing m\n                    <jats:sup>7<\/jats:sup>\n                    G modification by METTL1 knockdown significantly attenuated CAFs\u2019 stimulatory effect on osimertinib resistance both in vitro and in vivo. Our study revealed a novel mechanism that CAFs conferred osimertinib resistance in NSCLC cells through modulating m\n                    <jats:sup>7<\/jats:sup>\n                    G modification. These findings underscore the importance of m\n                    <jats:sup>7<\/jats:sup>\n                    G modification in the communication between cancer cells and the TME, and pave the way for finding novel therapeutic strategies to overcome drug resistance by targeting m\n                    <jats:sup>7<\/jats:sup>\n                    G modification.\n                  <\/jats:p>","DOI":"10.1038\/s41419-026-08505-7","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T18:14:03Z","timestamp":1771697643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m7G modification"],"prefix":"10.1038","volume":"17","author":[{"given":"Yongmei","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8158-3399","authenticated-orcid":false,"given":"Ke","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"8505_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med"},{"key":"8505_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:499\u2013514.","journal-title":"Nat Rev Clin Oncol"},{"key":"8505_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12672-025-01825-8","volume":"16","author":"R Shi","year":"2025","unstructured":"Shi R, Zhang N, Li H, Zhong H, Zhong C, Du W, et al. Cancer-associated fibroblast-derived COL17A1 promotes gemcitabine resistance and tumorigenesis in pancreatic cancer cells by interacting with ACTN4. Discov Oncol. 2025;16:118.","journal-title":"Discov Oncol"},{"key":"8505_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06246-3","volume":"23","author":"K Zhang","year":"2025","unstructured":"Zhang K, Guo L, Li X, Hu Y, Luo N. Cancer-associated fibroblasts promote doxorubicin resistance in triple-negative breast cancer through enhancing ZFP64 histone lactylation to regulate ferroptosis. J Transl Med. 2025;23:247.","journal-title":"J Transl Med"},{"key":"8505_CR5","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1111\/cas.13998","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Li X, Ren Y, Geng H, Zhang Q, Cao L, et al. Cancer-associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells. Cancer Sci. 2019;110:1609\u201320.","journal-title":"Cancer Sci"},{"key":"8505_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cac2.12414","volume":"43","author":"JW Eun","year":"2023","unstructured":"Eun JW, Yoon JH, Ahn HR, Kim S, Kim YB, Lim SB, et al. Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib. Cancer Commun. 2023;43:455\u201379.","journal-title":"Cancer Commun"},{"key":"8505_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s12672-025-01974-w","volume":"16","author":"G Wei","year":"2025","unstructured":"Wei G, Fan L, Song X, Zhou W, Sun M, Sun Y, et al. Modulation of almonertinib resistance in non-small cell lung cancer by cancer-associated fibroblasts through HK2-mediated glycolysis and SKP2 signaling. Discov Oncol. 2025;16:187.","journal-title":"Discov Oncol"},{"key":"8505_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-06064-z","volume":"23","author":"G Wei","year":"2025","unstructured":"Wei G, Nie Y, Sun M, Zhou W, Zhao H, Chen F, et al. Cancer-associated fibroblasts induce almonertinib resistance in non-small cell lung cancer. J Transl Med. 2025;23:42.","journal-title":"J Transl Med"},{"key":"8505_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.653","volume":"5","author":"Y Huang","year":"2024","unstructured":"Huang Y, Wang X, Wen C, Wang J, Zhou H, Wu L. Cancer-associated fibroblast-derived colony-stimulating factor 2 confers acquired osimertinib resistance in lung adenocarcinoma via promoting ribosome biosynthesis. MedComm. 2024;5:e653.","journal-title":"MedComm"},{"key":"8505_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1007\/s00109-023-02384-7","volume":"101","author":"F Takatsu","year":"2023","unstructured":"Takatsu F, Suzawa K, Tomida S, Thu YM, Sakaguchi M, Toji T, et al. Periostin secreted by cancer-associated fibroblasts promotes cancer progression and drug resistance in non-small cell lung cancer. J Mol Med. 2023;101:1603\u201314.","journal-title":"J Mol Med"},{"key":"8505_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03528-6","volume":"24","author":"S Zhang","year":"2024","unstructured":"Zhang S, Liu Y, Liu K, Hu X, Gu X. A review of current developments in RNA modifications in lung cancer. Cancer Cell Int. 2024;24:347.","journal-title":"Cancer Cell Int"},{"key":"8505_CR12","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.7150\/ijbs.79467","volume":"19","author":"M Chen","year":"2023","unstructured":"Chen M, Zhang Q, Zheng S, Guo X, Ren Y, Qian Y, et al. Cancer-associated fibroblasts promote migration and invasion of non-small cell lung cancer cells via METTL3-mediated RAC3 m6A modification. Int J Biol Scie. 2023;19:1616\u201332.","journal-title":"Int J Biol Scie"},{"key":"8505_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41401-023-01178-4","volume":"45","author":"QC Zhang","year":"2024","unstructured":"Zhang QC, Qian YM, Ren YH, Chen MM, Cao LM, Zheng SJ, et al. Phenethyl isothiocyanate inhibits metastasis potential of non-small cell lung cancer cells through FTO mediated TLE1 m(6)A modification. Acta Pharmacol Sin. 2024;45:619\u201332.","journal-title":"Acta Pharmacol Sin"},{"key":"8505_CR14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-025-01665-7","volume":"18","author":"Q Wu","year":"2025","unstructured":"Wu Q, Fu X, Liu G, He X, Li Y, Ou C. N7-methylguanosine modification in cancers: from mechanisms to therapeutic potential. J Hematol Oncol. 2025;18:12.","journal-title":"J Hematol Oncol"},{"key":"8505_CR15","doi-asserted-by":"publisher","first-page":"76116","DOI":"10.18632\/oncotarget.18814","volume":"8","author":"L Wang","year":"2017","unstructured":"Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6\/STAT3 signaling pathway. Oncotarget. 2017;8:76116\u201328.","journal-title":"Oncotarget"},{"key":"8505_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04150-4","volume":"12","author":"Y Ren","year":"2021","unstructured":"Ren Y, Cao L, Wang L, Zheng S, Zhang Q, Guo X, et al. Autophagic secretion of HMGB1 from cancer-associated fibroblasts promotes metastatic potential of non-small cell lung cancer cells via NFkappaB signaling. Cell Death Dis. 2021;12:858.","journal-title":"Cell Death Dis"},{"key":"8505_CR17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.tranon.2019.02.006","volume":"12","author":"P Shi","year":"2019","unstructured":"Shi P, Zhang S, Zhu L, Qian G, Ren H, Ramalingam SS, et al. The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations. Transl Oncol. 2019;12:705\u201313.","journal-title":"Transl Oncol"},{"key":"8505_CR18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.taap.2017.02.017","volume":"321","author":"ZH Tang","year":"2017","unstructured":"Tang ZH, Cao WX, Su MX, Chen X, Lu JJ. Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2017;321:18\u201326.","journal-title":"Toxicol Appl Pharmacol"},{"key":"8505_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.710","volume":"5","author":"TC Dakal","year":"2024","unstructured":"Dakal TC, Bhushan R, Xu C, Gadi BR, Cameotra SS, Yadav V, et al. Intricate relationship between cancer stemness, metastasis, and drug resistance. MedComm. 2024;5:e710.","journal-title":"MedComm"},{"key":"8505_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13045-022-01285-5","volume":"15","author":"Y Luo","year":"2022","unstructured":"Luo Y, Yao Y, Wu P, Zi X, Sun N, He J. The potential role of N(7)-methylguanosine (m7G) in cancer. J Hematol Oncol. 2022;15:63.","journal-title":"J Hematol Oncol"},{"key":"8505_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.omto.2022.05.009","volume":"26","author":"W Cheng","year":"2022","unstructured":"Cheng W, Gao A, Lin H, Zhang W. Novel roles of METTL1\/WDR4 in tumor via m(7)G methylation. Mol Ther Oncolytics. 2022;26:27\u201334.","journal-title":"Mol Ther Oncolytics"},{"key":"8505_CR22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.tcb.2022.07.001","volume":"32","author":"Y Chen","year":"2022","unstructured":"Chen Y, Lin H, Miao L, He J. Role of N7-methylguanosine (m(7)G) in cancer. Trends Cell Biol. 2022;32:819\u201324.","journal-title":"Trends Cell Biol"},{"key":"8505_CR23","volume":"6","author":"Y Uehara","year":"2025","unstructured":"Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, et al. Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in EGFR-Mutated Lung Adenocarcinoma. JTO Clin Res Rep. 2025;6:100779.","journal-title":"JTO Clin Res Rep"},{"key":"8505_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"M Huang","year":"2023","unstructured":"Huang M, Long J, Yao Z, Zhao Y, Zhao Y, Liao J, et al. METTL1-Mediated m7G tRNA Modification Promotes Lenvatinib Resistance in Hepatocellular Carcinoma. Cancer Res. 2023;83:89\u2013102.","journal-title":"Cancer Res"},{"key":"8505_CR25","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1038\/s41388-022-02250-9","volume":"41","author":"B Chen","year":"2022","unstructured":"Chen B, Jiang W, Huang Y, Zhang J, Yu P, Wu L, et al. N(7)-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT\/beta-catenin pathway in nasopharyngeal carcinoma. Oncogene. 2022;41:2239\u201353.","journal-title":"Oncogene"},{"key":"8505_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trsl.2024.01.009","volume":"268","author":"J Chen","year":"2024","unstructured":"Chen J, Zhou Q, Li S, Ling R, Zhao Y, Chen D, et al. Metabolic reprogramming driven by METTL1-mediated tRNA m7G modification promotes acquired anlotinib resistance in oral squamous cell carcinoma. Transl Res. 2024;268:28\u201339.","journal-title":"Transl Res"},{"key":"8505_CR27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41388-023-02882-5","volume":"43","author":"M He","year":"2024","unstructured":"He M, Wang Y, Xie J, Pu J, Shen Z, Wang A, et al. M(7)G modification of FTH1 and pri-miR-26a regulates ferroptosis and chemotherapy resistance in osteosarcoma. Oncogene. 2024;43:341\u201353.","journal-title":"Oncogene"},{"key":"8505_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.70363","volume":"29","author":"Q Yin","year":"2025","unstructured":"Yin Q, Lin D, Zeng W, Gu S, Zhu C, Liang C, et al. EZH2-Mediated PHF10 Suppression Amplifies HMGB1\/NF-kappaB Axis That Confers Chemotherapy Resistance in Cholangiocarcinoma. J Cell Mol Med. 2025;29:e70363.","journal-title":"J Cell Mol Med"},{"key":"8505_CR29","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3892\/ijo.2024.5708","volume":"66","author":"Q Kong","year":"2025","unstructured":"Kong Q, Liang Q, Tan Y, Luo X, Ling Y, Li X, et al. Induction of ferroptosis by SIRT1 knockdown alleviates cytarabine resistance in acute myeloid leukemia by activating the HMGB1\/ACSL4 pathway. Int J Oncol. 2025;66:2.","journal-title":"Int J Oncol"},{"key":"8505_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e29859","volume":"10","author":"W Liu","year":"2024","unstructured":"Liu W, Zhang Z, Zhang L, Jiang X, Chen C, Wu X, et al. Gfi-1 modulates HMGB1-Mediated autophagy to overcome oxaliplatin resistance in colorectal cancer. Heliyon. 2024;10:e29859.","journal-title":"Heliyon"},{"key":"8505_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s41065-023-00294-9","volume":"160","author":"Y Ma","year":"2023","unstructured":"Ma Y, Feng Q, Han B, Yu R, Jin Z. Elevated HMGB1 promotes the malignant progression and contributes to cisplatin resistance of non-small cell lung cancer. Hereditas. 2023;160:33.","journal-title":"Hereditas"},{"key":"8505_CR32","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3724\/abbs.2022023","volume":"54","author":"T Lei","year":"2022","unstructured":"Lei T, Huang J, Xie F, Gu J, Cheng Z, Wang Z. HMGB1-mediated autophagy promotes gefitinib resistance in human non-small cell lung cancer. Acta Biochimica et Biophysica Sinica. 2022;54:514\u201323.","journal-title":"Acta Biochimica et Biophysica Sinica"},{"key":"8505_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergen.2024.05.002","volume":"286-287","author":"D Liu","year":"2024","unstructured":"Liu D, Shen M, Liu Z, Chen D, Pan Y, Zhang L, et al. SP1-induced circ_0017552 modulates colon cancer cell proliferation and apoptosis via up-regulation of NET1. Cancer Genet. 2024;286-287:1\u201310.","journal-title":"Cancer Genet"},{"key":"8505_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/16078454.2021.2008590","volume":"27","author":"X Yang","year":"2022","unstructured":"Yang X, Li Y, Zhang Y, Liu J. Circ_0000745 promotes acute lymphoblastic leukemia progression through mediating miR-494-3p\/NET1 axis. Hematology. 2022;27:11\u201322.","journal-title":"Hematology"},{"key":"8505_CR35","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1080\/21655979.2021.1922052","volume":"12","author":"F Zhao","year":"2021","unstructured":"Zhao F, Zhao Z, Han Y, Li S, Liu C, Jia K. Baicalin suppresses lung cancer growth phenotypes via miR-340-5p\/NET1 axis. Bioengineered. 2021;12:1699\u2013707.","journal-title":"Bioengineered"},{"key":"8505_CR36","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.trecan.2024.11.005","volume":"11","author":"PSW Cheng","year":"2025","unstructured":"Cheng PSW, Zaccaria M, Biffi G. Functional heterogeneity of fibroblasts in primary tumors and metastases. Trends Cancer. 2025;11:135\u201353.","journal-title":"Trends Cancer"},{"key":"8505_CR37","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322\u201332.","journal-title":"Exp Mol Med"},{"key":"8505_CR38","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ccell.2021.09.003","volume":"39","author":"H Hu","year":"2021","unstructured":"Hu H, Piotrowska Z, Hare PJ, Chen H, Mulvey HE, Mayfield A, et al. Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms. Cancer Cell. 2021;39:1531\u201347.e10.","journal-title":"Cancer Cell"},{"key":"8505_CR39","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.3390\/cancers14143486","volume":"14","author":"D Kim","year":"2022","unstructured":"Kim D, Kim JS, Cheon I, Kim SR, Chun SH, Kim JJ, et al. Identification and Characterization of Cancer-Associated Fibroblast Subpopulations in Lung Adenocarcinoma. Cancers. 2022;14:3486.","journal-title":"Cancers"},{"key":"8505_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","volume":"42","author":"L Cords","year":"2024","unstructured":"Cords L, Engler S, Haberecker M, Ruschoff JH, Moch H, de Souza N, et al. Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer. Cancer Cell. 2024;42:396\u2013412.e5.","journal-title":"Cancer Cell"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08505-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08505-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:17:57Z","timestamp":1772795877000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08505-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8505"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08505-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"31 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Specifically, all experiments involving animals in this study were conducted according to the ethical policies and procedures approved by the Institutional Animal Care and Use Committee of Tianjin Medical University General Hospital (TMUGH) (No. IRB2023-DWFL-273). The use of human tissue in this study was approved by the Institutional Ethical Review Committee of TMUGH (No. IRB2023-KY-199). Informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"248"}}